Stock LLY ELI LILLY AND COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-02 pm EDT 		After market 07:54:42 pm
755.9 USD -2.68% Intraday chart for Eli Lilly and Company 745 -1.44%
May. 02 Novo Nordisk, Eli Lilly's Weight-Loss Drugs Get Price Cuts in UK MT
May. 02 Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1 RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 126,190 153,067 250,419 347,613 524,224 680,625 - -
Enterprise Value (EV) 1 139,069 165,981 263,395 361,640 546,522 700,607 695,911 689,650
P/E ratio 14.8 x 24.9 x 45.1 x 53 x 101 x 56.3 x 41.2 x 32 x
Yield 1.96% 1.75% 1.23% 1.07% 0.78% 0.69% 0.79% 0.87%
Capitalization / Revenue 5.65 x 6.24 x 8.84 x 12.2 x 15.4 x 15.9 x 13.1 x 11 x
EV / Revenue 6.23 x 6.76 x 9.3 x 12.7 x 16 x 16.4 x 13.3 x 11.2 x
EV / EBITDA 18.4 x 19.3 x 26.3 x 38.2 x 63.7 x 44.7 x 32.8 x 25.6 x
EV / FCF 36.6 x 32.5 x 44.3 x 69.1 x 690 x 83.6 x 50.7 x 37.6 x
FCF Yield 2.73% 3.08% 2.26% 1.45% 0.15% 1.2% 1.97% 2.66%
Price to Book 48.3 x 28.6 x 29.4 x 32.7 x 48.9 x 38.9 x 24.1 x 16.2 x
Nbr of stocks (in thousands) 960,131 906,582 906,592 950,178 899,307 900,405 - -
Reference price 2 131.4 168.8 276.2 365.8 582.9 755.9 755.9 755.9
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,320 24,540 28,318 28,541 34,124 42,764 52,132 61,638
EBITDA 1 7,551 8,589 10,005 9,472 8,584 15,689 21,239 26,888
EBIT 1 6,079 7,265 8,457 7,950 7,057 14,548 19,720 25,336
Operating Margin 27.24% 29.6% 29.86% 27.85% 20.68% 34.02% 37.83% 41.1%
Earnings before Tax (EBT) 1 5,266 7,230 6,156 6,806 6,555 13,795 18,069 21,429
Net income 1 8,318 6,194 5,582 6,245 5,240 11,935 16,289 21,045
Net margin 37.27% 25.24% 19.71% 21.88% 15.36% 27.91% 31.25% 34.14%
EPS 2 8.890 6.790 6.120 6.900 5.800 13.43 18.36 23.62
Free Cash Flow 1 3,803 5,112 5,951 5,230 792.5 8,384 13,717 18,325
FCF margin 17.04% 20.83% 21.01% 18.32% 2.32% 19.61% 26.31% 29.73%
FCF Conversion (EBITDA) 50.36% 59.52% 59.48% 55.21% 9.23% 53.44% 64.58% 68.15%
FCF Conversion (Net income) 45.71% 82.53% 106.61% 83.75% 15.12% 70.25% 84.21% 87.08%
Dividend per Share 2 2.580 2.960 3.400 3.920 4.520 5.193 5.993 6.587
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 8,000 7,810 6,488 6,942 7,302 6,960 8,312 9,499 9,353 8,768 9,981 11,314 12,806 10,745 11,515
EBITDA 1 2,982 3,046 1,679 2,373 2,375 1,982 2,618 986.4 2,855 3,049 3,691 4,780 5,925 - -
EBIT 1 2,536 2,610 1,330 2,010 2,000 1,620 2,252 575.4 2,468 2,648 3,004 3,917 4,736 - -
Operating Margin 31.7% 33.42% 20.5% 28.96% 27.39% 23.27% 27.09% 6.06% 26.38% 30.2% 30.1% 34.62% 36.98% - -
Earnings before Tax (EBT) 1 - - - - - - 2,089 427.2 2,509 2,536 2,935 4,249 4,819 - -
Net income 1 1,726 1,903 952.5 1,452 1,938 1,345 1,763 -57.4 2,190 2,243 2,437 3,308 4,134 - -
Net margin 21.58% 24.36% 14.68% 20.91% 26.54% 19.32% 21.21% -0.6% 23.41% 25.58% 24.42% 29.23% 32.28% - -
EPS 2 1.900 - 1.050 1.610 2.140 1.490 1.950 -0.0600 2.420 2.480 2.745 3.656 4.556 - -
Dividend per Share 2 0.8500 0.9800 0.9800 0.9800 0.9800 1.130 1.130 1.130 1.130 1.300 1.300 1.300 1.299 - -
Announcement Date 2/3/22 4/28/22 8/4/22 11/1/22 2/2/23 4/27/23 8/8/23 11/2/23 2/6/24 4/30/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,879 12,914 12,976 14,027 22,298 19,982 15,286 9,024
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.706 x 1.504 x 1.297 x 1.481 x 2.598 x 1.274 x 0.7197 x 0.3356 x
Free Cash Flow 1 3,803 5,112 5,951 5,230 793 8,384 13,717 18,325
ROE (net income / shareholders' equity) 89.6% 175% 102% 73.2% 48.9% 82.4% 75.6% 67.3%
ROA (Net income/ Total Assets) 13.4% 14.4% 15.6% 14.6% 9.23% 17.5% 21.2% 24.6%
Assets 1 62,143 42,961 35,816 42,708 56,748 68,035 76,891 85,623
Book Value Per Share 2 2.720 5.900 9.410 11.20 11.90 19.40 31.40 46.70
Cash Flow per Share 2 5.170 7.120 7.960 7.830 4.690 15.40 20.00 25.20
Capex 1 1,034 1,388 1,310 1,854 3,448 3,704 2,822 2,927
Capex / Sales 4.63% 5.66% 4.63% 6.5% 10.1% 8.66% 5.41% 4.75%
Announcement Date 1/30/20 1/29/21 2/3/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
755.9 USD
Average target price
848.3 USD
Spread / Average Target
+12.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 325B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 235B
NOVARTIS AG Stock Novartis AG
+4.71% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 157B
AMGEN INC. Stock Amgen Inc.
-3.34% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. Financials Eli Lilly and Company